Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 6;14(1):10354.
doi: 10.1038/s41598-024-61159-3.

Levels of anti-topoisomerase I antibody correlated with short onset of cardiopulmonary involvement in Thai systemic sclerosis patients

Kamonwan Mulalin  1 , Ajanee Mahakkanukrauh  1 , Siraphop Suwannaroj  1 , Patnarin Pongkulkiat  1 , Tippawan Onchan  1 , Sawinee Kasa  2 , Chingching Foocharoen  3
Affiliations

Levels of anti-topoisomerase I antibody correlated with short onset of cardiopulmonary involvement in Thai systemic sclerosis patients

Kamonwan Mulalin et al. Sci Rep. .

Abstract

Anti-topoisomerase-I antibody (ATA) is associated with disease severity and internal organ involvement in patients with systemic sclerosis (SSc). The correlation between ATA levels and the clinical course of SSc is unclear. We aimed to determine the correlation between ATA level and survival time and the onset of internal organ fibrosis in SSc patients. This historical cohort study was conducted in adult SSc patients with quantitative tests of ATA between January 2019 and December 2022. Patients with overlap syndrome and no quantitative ATA test were excluded. According to the sample size calculation, and 10% compensated for missing data, a total of 153 patients were needed. The respective mean age on the study date and median ATA level was 59.9 ± 11.3 years and 370 U/mL (range 195-652). Most cases (107 cases; 69.9%) were the diffuse cutaneous SSc subset. According to a multivariable analysis, the ATA titer had a negative correlation with the onset of cardiac involvement (Rho - 0.47, p = 0.01), and had a positive correlation with skin thickness progression (Rho 0.39, p = 0.04). Eleven cases exhibited ATA levels < 7 U/mL and outlier ATA levels were excluded, 142 cases were included in the sensitivity analysis, and multivariable analysis showed the correlation between early onset of ILD and cardiac involvement (Rho - 0.43, p = 0.03 and Rho - 0.51, p = 0.01, respectively). The ATA level was correlated with neither the survival time nor the onset of renal crisis in both analyses. High ATA levels were correlated with a short onset of ILD and cardiac involvement and the presence of extensive skin tightness. Quantitative tests of ATA could serve as an effective tool for identifying patients at risk of an unfavorable prognosis.

Keywords: Anti-topoisomerase I; Autoantibody; Interstitial lung disease; Scleroderma and related disorders; Systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study flow.
See this image and copyright information in PMC

References

    1. Systemic Sclerosis, Scleroderma—ClinicalKey. https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780123849298000332
    1. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: Incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr. Opin. Rheumatol. 2012;24:165–170. doi: 10.1097/BOR.0b013e32834ff2e8. - DOI - PubMed
    1. LeRoy EC, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J. Rheumatol. 1988;15:202–205. - PubMed
    1. Piantoni S, Franceschini F, Fredi M, Andreoli L, Tincani A. Topoisomerase I (SCL 70) autoantibodies, Chapter 29. In: Shoenfeld Y, Meroni PL, Gershwin ME, editors. Autoantibodies. 3. Elsevier; 2014. pp. 239–245.
    1. Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49:399–412. doi: 10.1002/art.11113. - DOI - PubMed

Publication types